Eli Lilly and Co., US5324571083

Eli Lilly and Company stock: Calytrix deal reaches $1.5 billion

Published on 11/17/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Company stock is in focus after the drugmaker agreed to buy Calytrix Bio. The deal could reach 1.5 billion US dollars.

Lilly expands its blood cancer pipeline

  • Lilly agreed to acquire privately held Calytrix Bio in a cash transaction worth up to 1.5 billion US dollars.
  • The deal adds an early-stage antibody program targeting mutated calreticulin in essential thrombocythemia and myelofibrosis.
  • Payment includes an undisclosed upfront amount and milestone payments tied to clinical and regulatory progress.
Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Eli Lilly and Company agreed on November 16, 2026, to acquire privately held Calytrix Bio for up to 1.5 billion US dollars in cash, according to Reuters. The transaction broadens Lilly's focus in hematology as the company seeks to diversify beyond its diabetes and obesity medicines.

Under the agreement, Calytrix shareholders could receive up to 1.5 billion US dollars. The consideration consists of an undisclosed upfront payment and additional amounts linked to clinical and regulatory milestones. The companies did not disclose the size of the upfront payment or when the transaction is expected to close.

A preclinical bet on rare blood cancers

Calytrix's lead program is an experimental antibody aimed at essential thrombocythemia and myelofibrosis, rare disorders in which the bone marrow produces abnormal blood cells. The treatment targets mutated calreticulin, a genetic alteration associated with the diseases, and is designed to attack abnormal cells while preserving healthy blood-forming cells.

The candidate has not yet entered human clinical trials, making the transaction an early-stage pipeline investment rather than a deal around an approved product. Lilly already markets the blood cancer medicine Jaypirca and acquired Ajax Therapeutics for 2.3 billion US dollars earlier in 2026, according to Reuters. The Calytrix agreement therefore adds another research asset to Lilly's expanding hematology portfolio while leaving clinical and regulatory execution as the main milestones ahead.

Eli Lilly and Company stock traded at 1,285.90 euros on Lang & Schwarz at 13:32 CET on Tuesday, November 17, 2026.

Eli Lilly and Company

  • Company: Eli Lilly and Company
  • ISIN: US5324571083
  • US ticker: LLY
  • Primary exchange: NYSE
  • Lang & Schwarz price: 1,285.90 euros at 13:32 CET on November 17, 2026

Lilly's primary listing places the company in the US equity market, with the S&P 500 as the broader benchmark.

More news and analyses on Eli Lilly and Company stock

Disclaimer...
en | US5324571083 | ELI LILLY AND CO. | boerse | 70526813 | bgmi